PVC/DEHP
This article was originally published in The Gray Sheet
Executive Summary
CDRH issues 1"Dear Colleague" letter to health providers July 12 listing 10 procedures posing the highest risk of exposure to di(2-ethylhexyl)phthalate, a plasticizer added to polyvinyl chloride that may be harmful to male reproductive organs. The health notice is based on a safety assessment completed by the agency in September (2"The Gray Sheet" Sept. 10, 2001, p. 18). For some high-risk procedures, "PVC devices that do not contain DEHP can be substituted, or devices made of other materials (such as ethylene vinyl acetate (EVA), silicone, polyethylene or polyurethane) can be used," the notice advises...
You may also be interested in...
DEHP Study Prompts FDA To Consider Safety/Availability Of PVC Alternatives
FDA will examine the safety and availability of alternatives to devices containing the plasticizer di-2-ethylhexyl-phthalate (DEHP) before considering a risk management strategy.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.